Clinical relevance of biomarkers in oestrogen receptor positive breast cancer

Parks, R. M.; Cheung, K. L.

Abstract

© 2020 Nova Science Publishers, Inc. Some biomarkers have been examined extensively in the context of breast cancer, including the oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). They are now routinely measured and used clinically for selection of primary, (neo)adjuvant endocrine therapy and/or chemotherapy. In this chapter, we will review the literature, including the work of our group, on the analysis of biomarkers (including those that are not routinely measured clinically but may be relevant in ER positive breast cancer e.g., B-cell lymphoma (BCL) 2-protein, Ki-67, and p53). We will specifically look at the relationship of these biomarkers with age and their potential clinical relevance, notably their prognostic value and ability to predict therapeutic response. Furthermore, we will discuss the potential technology of high-throughput measurement of these biomarkers at diagnosis for use as tools for clinical assessment and research.

Citation

Parks, R. M., & Cheung, K. L. (2020). Clinical relevance of biomarkers in oestrogen receptor positive breast cancer. In G. G. Chen, M. C. Tong, & C. van Hasselt (Eds.), Estrogen receptors: structure, functions and clinical aspects (53-91). Nova Science Publishers

• Acceptance Date: Jun 2, 2020
• Publication Date: 2020-08
• Deposit Date: Aug 24, 2020
• Publicly Available Date: Mar 1, 2021
• Publisher: Nova Science Publishers
• Pages: 53-91
• Book Title: Estrogen receptors: structure, functions and clinical aspects
• Chapter Number: 3
• ISBN: 9781536182286
• Public URL: https://nottingham-repository.worktribe.com/output/4849366
• Publisher URL: https://novapublishers.com/shop/estrogen-receptors-structure-functions-and-clinical-aspects/